Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023
02 août 2023 16h01 HE
|
Journey Medical Corporation
Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET Company and Neal Bhatia, MD, Director of Clinical Dermatology,...
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
19 juil. 2023 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., July 19, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
11 juil. 2023 08h30 HE
|
Journey Medical Corporation
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues DFD-29 demonstrated statistical...
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023
03 juil. 2023 08h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling...
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects
13 juin 2023 08h30 HE
|
Journey Medical Corporation
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with...
Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
22 mai 2023 16h01 HE
|
Journey Medical Corporation
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023 Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29 Company to hold...
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023
19 mai 2023 16h01 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 19, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023
04 mai 2023 09h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 04, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...
Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
29 mars 2023 16h01 HE
|
Journey Medical Corporation
Generated record total revenues of $73.7 million for the full year 2022 Completed enrollment in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea; topline data...
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023
22 mars 2023 09h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 22, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...